M. Békradda

发表

New possibilities in chemotherapy for colorectal cancer.

E. Cvitkovic, M. Békradda, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: The Institut Gustave Roussy experience

S. Culine, C. Théodore, J. Droz, 1996, Cancer.

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

M. D’Incalci, E. Erba, L. Beltrame, 2016, Oncotarget.

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

B. Leber, P. Hérait, K. Rai, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer.

P. Soulié, E. Brain, M. Bekradda, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I /II S tudy o f E scalating D oses o f V inorelbine i n Combination W ith O xaliplatin i n P atients W ith A dvanced Non-Small-Cell L ung C ancer

P. Soulié, E. Brain, M. Bekradda, 2001 .

Prognostic factors for survival in patients with brain metastases from renal cell carcinoma

S. Culine, J. Droz, B. Escudier, 1998, Cancer.

Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.

P. Soulié, J. Misset, P. Canal, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin clinical activity: a review.

J. Misset, E. Cvitkovic, H. Bleiberg, 2000, Critical reviews in oncology/hematology.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

E. Raymond, G. Inghirami, M. D’Incalci, 2016, Oncotarget.

OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models

L. Ouafik, Kay Noel, M. Riveiro, 2016, International journal of cancer.

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.

G. Pelosi, A. Stathis, E. Uro-Coste, 2016, Cancer discovery.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

S. Peters, J. Soria, A. Stathis, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin for the treatment of advanced colorectal cancer: future directions.

M. Ducreux, M. Bekradda, E. Cvitkovic, 1998, Seminars in oncology.

Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.

J. Pierga, Y. Bécouarn, J. Raoul, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors.

E. Raymond, M. D’Incalci, R. Frapolli, 2015, Biochimie.

Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB).

M. Sanson, O. Chinot, A. Hottinger, 2016 .

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

B. Quesnel, P. Hérait, A. Stathis, 2016, Clinical Pharmacokinetics.

A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

S. Peters, J. Soria, A. Stathis, 2016 .

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy

L. Ouafik, O. Touzelet, M. Riveiro, 2021, Frontiers in Oncology.

Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.

S. Culine, C. Théodore, J. Droz, 1997, American journal of clinical oncology.

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK‐8628 in malignant pleural mesothelioma xenografts

F. Grosso, S. Orecchia, P. Ubezio, 2017, International journal of cancer.

Oxaliplatin: a new therapeutic option in colorectal cancer.

M. Bekradda, E. Cvitkovic, M. Békradda, 1999, Seminars in oncology.

Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

H. Wildiers, J. Canon, F. Bidard, 2020 .

High‐dose continuous‐infusion fosfestrol in hormone‐resistant prostate cancer

S. Culine, J. Droz, J. Kattan, 1993, Cancer.

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study.

P. Soulié, E. Brain, J. Misset, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients.

S. Culine, J. Trédaniel, J. Alexandre, 2009, Lung cancer.

Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients

P. Soulié, E. Brain, J. Misset, 1999, Journal of Cancer Research and Clinical Oncology.

[Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature].

S. Culine, J. Droz, J. Kattan, 1994, Bulletin du cancer.

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models

H. Dombret, E. Raymond, P. Hérait, 2019, Leukemia & lymphoma.

Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples

P. Hérait, M. Riveiro, Elodie Odore, 2014 .

Abstract 3530: Gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models

I. Kwee, F. Bertoni, M. Riveiro, 2015 .

Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy?

S. Culine, J. Droz, M. Terrier-Lacombe, 1995, European urology.

[Efficacy of the combination of 5 fluorouracil, adriamycin and cisplatin (FAP protocol) in the treatment of metastatic cylindroma. Apropos of a case with review of the literature].

S. Culine, J. Droz, J. Kattan, 1994, Bulletin du Cancer.

OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models

L. Ouafik, Kay Noel, M. Riveiro, 2016, International journal of cancer.

Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors.

E. Raymond, M. D’Incalci, R. Frapolli, 2015, Biochimie.

CPT-11 and L-OHP combination versus alternated combination of LV5FU2 + CPT-11/LV5FU2 + L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results

Y. Bécouarn, E. Gamelin, M. Mousseau, 1999 .